modelS01CA08
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | MethylprednisoloneAndAntiinfectives | |
| ATC code: | S01CA08 | route: |
| compartments: | 0 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Methylprednisolone and antiinfectives (ATC S01CA08) is a combination ocular drug preparation intended for the treatment of eye infections and inflammation. Methylprednisolone is a corticosteroid used for its anti-inflammatory and immunosuppressive properties, while the antiinfective component prevents or treats bacterial infections. This combination is primarily used in ophthalmology to manage inflammatory eye conditions with a concurrent risk or presence of infection. Not all countries have this specific combination approved, and its availability may vary.
Pharmacokinetics
No pharmacokinetic studies or published PK models specific to the combined preparation of methylprednisolone and antiinfectives (S01CA08) for ophthalmic use were identified in the literature. Thus, PK parameter values are not directly available.
References
Suetsugu, K, et al., & Ieiri, I (2021). Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Drugs in R&D 21(4) 419–429. DOI:10.1007/s40268-021-00365-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34655050
Wu, Y, et al., & Liu, T (2025). Drug-drug interaction of phenytoin sodium and methylprednisolone on voriconazole: a population pharmacokinetic model in children with thalassemia undergoing allogeneic hematopoietic stem cell transplantation. European journal of clinical pharmacology 81(3) 365–374. DOI:10.1007/s00228-024-03795-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39714727
Hodel, K, et al., & Godoy, AL (2024). Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects. Current pharmaceutical biotechnology 25(13) 1651–1663. DOI:10.2174/0113892010264503231108070917 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38258769
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)